uniQure N.V. Cash and Cash Equivalents, Period Increase (Decrease)
uniQure N.V. (QURE) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$28.41 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-08-08
- uniQure N.V. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$16.18M.
- uniQure N.V. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$12.22M.
- uniQure N.V. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-06-30 was -$25.75M.
- uniQure N.V. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-03-31 was -$11.95M.
- uniQure N.V. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$89.13M, a 156.79% decline from fiscal 2015.
- uniQure N.V. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $156.94M, a 391.80% increase from fiscal 2014.
- uniQure N.V. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $31.91M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|
| 2017-06-30 | -$16.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$28.41M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | -$12.22M 10-Q · filed 2017-05-09 | ||
| 2016-12-31 | -$89.13M 10-K · filed 2017-03-15 | ||
| 2016-06-30 | -$25.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$37.69M 10-Q · filed 2017-08-08 | |
| 2016-03-31 | -$11.95M 10-Q · filed 2017-05-09 | ||
| 2015-12-31 | $156.94M 10-K · filed 2017-03-15 | ||
| 2014-12-31 | $31.91M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |